基线肾功能受损可能不影响左心室辅助装置植入后的结局与生存
该回顾性研究纳入255例左心室辅助装置(LVAD)植入患者,按术前估算肾小球滤过率(eGFR)分为>60与<60 mL/min/1.73 m2两组及6个肾功能分级。结果显示,术前eGFR<60组术后1个月eGFR显著升高(P<.001),且4年时仍显著高于基线(P=.032);两组1、3、5年生存率无显著差异(P=.92)。结论认为术前肾功能不全不影响LVAD长期结局与生存。
要点
- LVAD植入后1个月整体eGFR从75.19升至118.97 mL/min/1.73 m2(P<.001)。
- 术前eGFR<60组术后1个月显著升高,4年时仍高于基线(P=.032)。
- 术前eGFR>60与<60组1、3、5年生存率无显著差异(P=.92)。
核心结论
- 术前eGFR低的患者可从LVAD治疗中获益,eGFR持续高于术前水平。
- 术前肾功能不全未对长期发病率与死亡率产生负面影响。
研究设计与样本
- 回顾性分析255例LVAD植入患者,按术前eGFR<60或>60 mL/min/1.73 m2分为2组,并分为6个肾功能分级。
主要发现
- 术后1个月总队列eGFR从基线75.19 ± 34.35升至118.97 ± 67.62 mL/min/1.73 m2(P < .001)。
- 术后4年eGFR高于基线但无统计学显著性(P = .48)。
- 术前eGFR<60组术后1个月显著升高(P < .001),4年时仍显著高于基线(P = .032)。
- 术前eGFR>60组1、3、5年生存率分别为76%、54%、48%,eGFR<60组分别为71%、60%、48%(P = .92)。
临床怎么用
- 术前肾功能不全不应作为LVAD植入的排除因素,术后肾功能可改善且长期生存不受影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated changes in estimated glomerular filtration rate (eGFR) after left ventricular assist device (LVAD) implant and the impact on long-term outcomes. METHODS: A retrospective analysis was conducted for 255 patients with LVADs, divided into 2 groups based on preimplant eGFR (<60 or >60 mL/min/1.73 m2) and into 6 grades (grade 1, >90 mL/min/1.73 m2 normal; grade 2, 60-89 mild dysfunction; grade 3, 45-59 moderate; grade 4, 30-44 moderate to severe; grade 5, 15-29 severe; or grade 6, <15 kidney failure). Changes in eGFR and the impact on long-term outcome and survival were analyzed. RESULTS: One-month postimplant eGFR of the total cohort increased from a baseline of 75.19 ± 34.35 to 118.97 ± 67.62 mL/min/1.73 m2(P < .001). eGRF 4 years postimplant was higher than baseline but not significantly (P = .48). Patients with a preimplant eGFR > 60 followed the same pattern as the entire cohort. The preimplant eGFR < 60 group had a significant increase at 1 month (P < .001), eGFR remained significantly higher than baseline 4 years postimplant (P = .032), and there was a sustained transition to improved distribution of renal function grade after LVAD implant. Post-LVAD implant survival at 1, 3, and 5 years for baseline eGFR > 60 was 76%, 54%, and 48% and for eGFR < 60 was 71%, 60%, and 48%, respectively (P = .92). CONCLUSIONS: Patients with a low preimplant eGFR derive benefit from LVAD therapy, with eGFR remaining elevated above preimplant levels. Preimplant renal dysfunction did not impact negatively on long-term morbidity and mortality.
引用
- Smail H, Hassan HA, Bowles C, et al. Impaired Baseline Renal Function May Not Influence Outcomes and Survival After Left Ventricular Assist Device Implantation. Ann Thorac Surg. 2020. PMID: 32698021. doi:10.1016/j.athoracsur.2020.05.127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。